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Background: Cross-sectional studies indicate that up to 80% of active 
SARS-CoV-2 infections may be asymptomatic. However, accurate 
estimates of the asymptomatic proportion require systematic 
detection and follow-up to differentiate between truly asymptomatic 
and pre-symptomatic cases. We conducted a rapid review and meta-
analysis of the asymptomatic proportion of PCR-confirmed SARS-CoV-
2 infections based on methodologically appropriate studies in 
community settings. 
Methods: We searched Medline and EMBASE for peer-reviewed 
articles, and BioRxiv and MedRxiv for pre-prints published before 
25/08/2020. We included studies based in community settings that 
involved systematic PCR testing on participants and follow-up 
symptom monitoring regardless of symptom status. We extracted 
data on study characteristics, frequencies of PCR-confirmed infections 
by symptom status, and (if available) cycle threshold/genome copy 
number values and/or duration of viral shedding by symptom status, 
and age of asymptomatic versus (pre)symptomatic cases. We 
computed estimates of the asymptomatic proportion and 95% 
confidence intervals for each study and overall using random effect 
meta-analysis.  
Results: We screened 1138 studies and included 21. The pooled 
asymptomatic proportion of SARS-CoV-2 infections was 23% (95% CI 
16%-30%). When stratified by testing context, the asymptomatic 
proportion ranged from 6% (95% CI 0-17%) for household contacts to 
47% (95% CI 21-75%) for non-outbreak point prevalence surveys with 
follow-up symptom monitoring. Estimates of viral load and duration of 
viral shedding appeared to be similar for asymptomatic and 
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symptomatic cases based on available data, though detailed reporting 
of viral load and natural history of viral shedding by symptom status 
were limited. Evidence into the relationship between age and 
symptom status was inconclusive. 
Conclusion: Asymptomatic viral shedding comprises a substantial 
minority of SARS-CoV-2 infections when estimated using 
methodologically appropriate studies. Further investigation into 
variation in the asymptomatic proportion by testing context, the 
degree and duration of infectiousness for asymptomatic infections, 
and demographic predictors of symptom status are warranted.
Keywords 
SARS-CoV-2, asymptomatic, COVID-19, pandemic, epidemiology
 
This article is included in the Coronavirus 
(COVID-19) collection.
 
Page 2 of 16
Wellcome Open Research 2020, 5:266 Last updated: 05 NOV 2020
Introduction
Reports of asymptomatic SARS-CoV-2 infection and poten-
tial transmission1–3 have generated concern regarding the 
implications of undetected asymptomatic transmission on the 
effectiveness of public health interventions in the current 
COVID-19 pandemic4. However, estimating the proportion of 
asymptomatic SARS-CoV-2 infections with viral shedding is 
challenging as the majority of testing is carried out on symp-
tomatic individuals5. Furthermore, longitudinal designs that 
include symptom follow-up are required to differentiate truly 
asymptomatic cases, i.e. those that never develop symptoms dur-
ing infection, from pre-symptomatic cases, i.e. those that shed 
virus and therefore test positive prior to symptom onset (see 
Figure 1). While asymptomatic viral shedding has been sug-
gested to comprise up to ~80% of SARS-CoV-2 infections6–8, 
data informing these figures are largely confined to cross-sec-
tional reports that cannot distinguish truly asymptomatic cases 
from those who are pre-symptomatic at the point of testing 
(see Figure 1). Interchangeable use of these concepts, i.e. 
asymptomatic and pre-symptomatic, precludes accurate estima-
tion of the asymptomatic proportion of potentially infectious 
SARS-CoV-2 cases. Detectible SARS-CoV-2 shedding based 
on reverse transcriptase polymerase chain reaction (PCR) test-
ing cannot conclusively establish infectiousness in the absence 
of viral culture9,10. However, PCR cycle threshold values provide 
an informative estimate of viral load and, by extension, prob-
able infectiousness9; consequently, PCR-confirmed infection 
can provide a useful and accessible indicator of potentially 
infectious cases, including those without symptoms, for 
epidemiological modelling.
Differences in demographic characteristics of asymptomatic 
versus symptomatic individuals are also poorly understood. 
Age is an important risk factor for COVID-19 severity, with 
greater risk of poor prognostic outcomes including mortal-
ity in older adults11,12. Consequently, asymptomatic infection 
may be less common with increasing age. Understanding the 
relationship between age and symptom status has important 
implications for public health interventions.
Given the widespread discussion and potential implications 
of asymptomatic transmission of SARS-CoV-2, we aimed to 
rapidly synthesize studies to estimate the asymptomatic pro-
portion of PCR-confirmed cases in community settings 
(primary outcome). We also aimed to synthesize available 
data from these studies regarding viral load and duration of 
viral shedding in asymptomatic community cases compared to 
pre-symptomatic cases or those symptomatic from baseline 
(secondary outcome), and the relationship between symptom 
status and age (secondary outcome). We limited the review 
to include studies from community settings rather than 
hospitals and other medical facilities to prevent selection 
bias towards symptomatic cases. Only studies reporting 
PCR-confirmed cases rather than exclusive serological stud-
ies were included to estimate the proportion of asymptomatic 
SARS-CoV-2 infection with viral shedding. The review 
was not extended to estimate the overall asymptomatic 
proportion including non-shedding serological cases due to 
the limited number of serological studies, varying interpre-
tation, and ongoing development of valid serological assays 
for SARS-CoV-2.
Methodology
This review was reported in line with the PRISMA 
guidelines13. A protocol was not registered due to its status as 
a rapid review.
Figure 1. Timeline of symptom development and viral shedding in relation to timing of virological testing. This figure demonstrates 
two trajectories of symptom development in cases with detectable viral shedding. The symptomatic case trajectory comprises a period of 
pre-clinical viral shedding, in which the individual demonstrates no symptoms but tests PCR positive (pre-symptomatic PCR-confirmed). 
These individuals subsequently develop symptoms and continue to shed virus (symptomatic PCR-confirmed). Consequently, cases with a 
symptomatic trajectory may appear to be asymptomatic if tested in the pre-clinical shedding period and not followed-up. Asymptomatic 
cases with viral shedding, conversely, test PCR positive and never go on to develop symptoms across the course of infection (asymptomatic 
PCR-confirmed).
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Search strategy
We used Ovid to search the Medline and EMBASE data-
bases of peer-reviewed literature (2019- May 05 2020 and 
search repeated to include period of May 06 2020 to June 10 
2020, and subsequently to include June 11 2020 to August 
25 2020) using the following search terms for titles and 
abstracts: (Coronavirus* OR Covid-19 OR SARS-CoV-2 OR 
nCoV) AND (asymptomatic) AND (polymerase chain reac-
tion OR PCR OR laboratory-confirmed OR confirmed). We 
also searched BioRxiv and MedRxiv for titles and abstracts 
of pre-print manuscripts using the terms “Covid-19” + 
“asymptomatic”. We hand-searched the reference lists of all 
included studies to identify any additional relevant literature.
Selection criteria
We included studies that met all of the following criteria: 
1) human study; AND 2) presented original research or 
public health COVID-19 surveillance data; AND 3) available 
in English; AND 4) presented data on polymerase chain reac-
tion (PCR) confirmed COVID-19 cases; AND 5) presented 
data on PCR testing of exposed or potentially exposed indi-
viduals regardless of symptom status (to avoid bias towards 
symptomatic cases); AND 6) had systematic follow-up at ≥ 
1 time-point and reporting of symptom status among PCR 
confirmed cases (to differentiate pre-clinical shedding from 
truly asymptomatic cases); AND 7) presented data from a com-
munity setting (i.e. community and home contact tracing, 
population screening, traveller screening, community insti-
tutional settings such as care homes, schools, or workplaces, 
occupational exposure including healthcare workers). Studies 
were excluded if they met any of the following criteria: 1) 
studies or case series with <5 positive cases and/or <20 total 
cases (small sample size) due to likely low generalisability 
of asymptomatic proportions; OR 2) not possible to con-
sistently ascertain the symptomatic status of participants 
across follow-up; OR 3) inadequate detail about testing 
strategy (i.e. not possible to discern if all cases were tested 
systematically); OR 4) recruitment/reporting of patients from 
acute healthcare settings (e.g. hospitals, medical facilities) 
due to selection bias towards symptomatic cases.
Data extraction and analysis
One researcher performed the search and deduplication using 
Ovid, screened and selected studies, and extracted study 
details. Two researchers extracted primary outcome data inde-
pendently and resolved any disagreement by consensus. We 
extracted the following variables of interest to assess the 
primary and secondary outcomes and the characteristics and 
quality of included studies: author names, year of publication, 
publication type (peer-reviewed article or pre-print), study 
design, study setting, study country of location, participant 
age (mean, median, or range as available), participant sex 
distribution, symptoms comprising symptomatic case definition, 
duration of symptom history at PCR-confirmation, duration 
of follow-up symptom monitoring, testing criteria, sample 
size, number of participants who underwent PCR test-
ing, number of PCR-confirmed cases, number of confirmed 
cases who remained asymptomatic throughout follow-up, and 
cycle threshold or genome copy number values, viral culture 
results, duration of viral shedding for asymptomatic and 
pre-/symptomatic cases, and any available data regarding age 
or age distribution of asymptomatic versus (pre)symptomatic 
cases if reported.
We performed random-effects meta-analysis using the metaprop 
programme14 in Stata Version 15 to compute the study-spe-
cific and pooled asymptomatic proportion - the primary out-
come of this review - with its 95% confidence intervals 
(Wilson score method) and 95% prediction intervals15, applying 
the Freeman-Tukey transformation (the same analysis 
can be performed in R). We decided a-priori to use a random 
effects model to address heterogeneity. The asymptomatic 
proportion is given as the number of consistently asymp-
tomatic confirmed cases divided by the total number of 
PCR-confirmed cases who received follow-up (Figure 2). It 
is important to note that the term asymptomatic proportion 
is sometimes used to alternatively refer to the asymptomatic 
proportion of all infections including those that do not shed 
virus and would not be PCR-confirmed (see Figure 2). To account 
for potential exposure-driven heterogeneity in asymptomatic 
proportion, we present findings stratified by testing context 
as well as overall. Testing context was subdivided into stud-
ies comprising exclusive household contacts of an index case, 
studies comprising contacts from other settings or those (poten-
tially) exposed to an outbreak (including travellers returning 
from high-prevalence regions), and point prevalence surveys 
not specifically linked to an outbreak that had follow-up 
symptom monitoring.
We reported available findings regarding the viral load, 
duration of viral shedding, and age of asymptomatic and 
(pre)symptomatic cases, but did not conduct meta-analysis due 
to sparse reporting and inconsistencies in data presented.
Risk of bias assessment
We assessed risk of bias based using criteria relevant to the 
topic of this review adapted from the Joanna Briggs Institute 
critical appraisal tool for prevalence studies16 (Table 1). Two 
researchers independently assessed the risk of bias for each 
included study and resolved any disagreement by consensus. 
Bias was assessed according to criteria described in Table 1, 
with studies graded as very low risk of bias if they were 
unlikely to have been affected by bias on any of the criteria, 
low if one criterion may have been affected, moderate if two 
may have been affected, and high if all three may have been 
affected. Risk of publication bias across included studies was 
assessed using a funnel plot and Egger’s test.
Results
Records identified
Figure 3 presents an adapted PRISMA flow diagram13 of the 
study selection procedure. The search yielded 1077 published 
articles indexed on OVID and 473 pre-prints. Following 
deduplication, we screened the titles and abstracts of 1138 
published articles and pre-prints, of which we assessed the 
133 full texts – including a relevant text identified through 
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Figure 2. Summary classification of clinical and PCR outcomes and calculation of asymptomatic proportions.
Table 1. Risk of bias assessment.
Potential Issue Direction of Bias
Information Bias: Initial testing does not identify 
all infected people shedding virus 
Effect estimate could be biased downwards if PCR testing is more likely to detect 
symptomatic shedders compared to asymptomatic shedders. This could be 
because asymptomatic cases shed less virus or shed for a shorter duration. 
Information Bias: Difficulty distinguishing pre-
clinical versus truly asymptomatic
Effect estimate could be biased upwards if pre-symptomatic cases are 
misclassified as asymptomatic (see Figure 1) 
Non-Participation Bias: Individuals opt out of 
initial PCR testing or out of symptom follow-up
Effect estimate could be biased in either direction if participation is influenced on 
symptom-status
hand-search of the literature – and included 21 in the present 
review17–37. Three of the 21 included studies comprised 
household contacts of confirmed cases26,28,29. A further three 
included studies were point prevalence surveys with symptom 
monitoring follow-up34–36, one of which was conducted in 
a general population sample36 and the remaining two in 
nursing home samples34,35. The remaining 15 studies involved 
participants with other epidemiological links to confirmed or 
suspected cases/outbreaks17–25,27,30–33, including five studies 
based in nursing homes18,19,24,32,37, and one study of healthcare 
workers with occupational exposure to confirmed cases30. 
The healthcare worker study was included as it comprised 
whole-facility testing following occupational exposure in 
healthcare workers rather than patients presenting to health-
care settings due to symptoms (see inclusion criteria). Studies 
were conducted across the following range of countries in 
Asia, Europe, and North America: China22,25–27,29, USA18,19,28,32,36, 
UK24,35,37, South Korea17, France20, Vietnam21, Brunei23, Italy30, 
Japan31, Hong Kong33, and Ireland34. Risk of bias was rated as 
very low for two studies30,33, low for 15 studies17–20,22,23,25–29,32,34–36, 
and moderate for four studies21,24,31,37.
Asymptomatic proportion of PCR-confirmed SARS-CoV-
2 infections in community settings
Estimates of the asymptomatic proportion of PCR-posi-
tive SARS-CoV-2 infections for included studies ranged 
from 0% (95% CI 0-0.8%; Yousaf et al.28) to 91% (95% CI 
73%-98%; Starling et al., 202035). Table 2 reports all asymp-
tomatic proportions with 95% confidence intervals for as 
well as details of included studies. Based on random-effects 
meta-analysis (Figure 4), the pooled estimate for the asympto-
matic proportion was 23% (95% CI 16%-30%; 95% prediction 
interval 0.01-57%). There was high heterogeneity: Q(20)= 
253.06, p<.001, τ2= 0.11, I2= 92.10%. Heterogeneity appeared 
to be partly influenced by testing context (test for subgroup 
heterogeneity: Q(2) = 10.49, p=0.01), but remained substantial 
within these subgroups. Household contact studies demonstrated 
the lowest asymptomatic proportion estimate of 6% (95% 
CI 0-17%; heterogeneity Q(2)= 12.09, p<.001 τ2= 0.07, 
I2= 83.46%), rising to 23% (95% CI 14-32%; Q(14)= 139.86, 
p<.001 τ2= 0.12, I2= 89.99%) for studies comprising 
participants with other epidemiological links to SARS-CoV-2 
cases or outbreaks, and 47% (95% CI 21-75%; Q(2)= 47.16, 
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Figure 3. Adapted PRISMA flow diagram of study selection.
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Figure 4. Meta-analysis results for COVID-19 asymptomatic proportion in community studies. ES (effect size) = asymptomatic 
proportion; I^2 = heterogeneity; asymptomatic proportions are given in decimal form.
p<.001 τ2= 0.23, I2= 95.76%) for point prevalence surveys with 
symptom follow-up and without direct links to outbreaks/cases. 
Data were limited for studies exclusively involving household 
contacts or point prevalence surveys (both n=3 studies).
The funnel plot (Figure 5) and Egger’s test did not indicate 
publication bias across studies included in the meta-analysis: 
t=0.23, p=0.82, 95% CI: -0.97, 1.20.
Viral load and duration of viral shedding
Eight of the twenty-one included studies reported data 
regarding the CT values/viral load and/or duration of viral 
shedding for asymptomatic cases versus pre-symptomatic 
cases and/or those symptomatic from baseline. Differences in 
methodology and reporting precluded meta-analysis.
Five studies reported CT values and/or genome copy number 
by symptom status. One of these studies, Hung et al.33, found 
lower median baseline genome copy number in asympto-
matic (3.86 log10 copies/mL) than symptomatic participants 
(7.62 log10 copies/mL). The remaining four studies all 
reported similar CT values for asymptomatic and symptomatic 
participants. Arons et al.18 reported similar baseline median 
cycle threshold values (CT) for asymptomatic (CT =25.5), 
pre-symptomatic (CT=23.1), and symptomatic (CT=24.5) 
cases. Infectious virus was isolated by viral culture from 33% 
(1/3) of available asymptomatic case specimens, 70.8% (17/24) 
of pre-symptomatic case specimens, and 65.0% (16/20) 
for symptomatic case specimens18. Chamie et al. (2020)36 
also found that median CT values across samples were 
not significantly different between asymptomatic (CT=24, 
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Figure 5. Funnel plot for meta-analysis of COVID-19 asymptomatic proportion in community studies.
IQR: 19-26) and symptomatic individuals (CT=24, IQR: 19-25). 
Pre-symptomatic individuals appeared to have higher median 
CT values if seronegative and similar values if seroposi-
tive, but numerical detail was not reported overall for this 
group. Ladhani et al. (2020)37 also found no significant 
difference in baseline CT values between asymptomatic, pre-
symptomatic, symptomatic, and post-symptomatic (i.e. reported 
symptoms in the two weeks prior to positive PCR result) 
participants; exact values were not provided. Chau et al.21 also 
reported similar baseline cycle threshold values for asympto-
matic and symptomatic cases, though further numeric detail 
was not reported. When including all PCR results across 
follow-up for asymptomatic versus symptomatic cases (includ-
ing negative PCR results), asymptomatic cases appeared to 
demonstrate lower CT values overall, which was proposed 
to indicate faster viral clearance21.
Direct investigation of duration of viral shedding was limited. 
Lombardi et al.30 found that median duration from posi-
tive test to first negative test was shorter in asymptomatic 
participants (22 days; IQR: 15–30) than symptomatic ones 
(29 days; IQR: 24–31), but the difference was not statisti-
cally significant. Danis et al.20 reported that the single asymp-
tomatic case demonstrated the same viral load dynamics 
as one of the five symptomatic cases, with respective viral 
shedding periods of 7 and 6 days.
Age of symptomatic versus asymptomatic cases
Six studies21,27,29,31,33,37 reported information regarding the age 
of asymptomatic versus symptomatic cases. Variation in meas-
urement and reporting precluded meta-analysis. Findings are 
reported in Table 3. Three studies indicated no significant dif-
ference in age between symptomatic and asymptomatic cases, 
while three studies suggested that asymptomatic cases tended 
to be younger than those with symptoms. Five studies were 
conducted in general population samples (contacts/potential 
contacts of confirmed cases or returning travellers), and one 
study was conducted in nursing home residents and staff with 
results stratified for these groups. Only one study29 reported a 
substantial child sub-sample (<14 years old), and found a 
higher asymptomatic proportion for infected children (23% 
n=10/43) than adults (7%, n=8/108).
Discussion
Accurate estimates of the asymptomatic proportion of 
SARS-CoV-2 infections depend on appropriate study designs 
that systematically detect asymptomatic viral shedding and 
follow these cases up to differentiate truly asymptomatic 
infections from pre-clinical shedding. We calculated that an 
overall estimate of 23% of PCR-confirmed SARS-CoV-2 infec-
tions in community settings were asymptomatic, with a 95% 
confidence interval between 16%-30%. These findings do 
not support claims6–8 of a very high asymptomatic proportion 
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Table 3. Reported findings for age of asymptomatic versus symptomatic cases.
Study Sample Findings
Chau et al. 
(2020)
General public (contacts of 
confirmed case or returning 
travellers)
Median age of asymptomatic versus symptomatic participants: 30 (range 16-
60) versus 27 (range 18-58)
Yang et al. 
(2020)
General public exposed to index 
case on flight
Median age of asymptomatic and symptomatic participants: 26 (IQR: 25.5-
26.5) versus 33 (IQR: 29-45) 
 
*note: very small asymptomatic sample (n=2)
Hua et al. 
(2020)
General public exposed to 
household cases or returning 
from high-risk areas
23% of infected children (≤14 years, n=10/43) were asymptomatic versus 
7% of infected adults (n=8/108), with children comprising 56% (n= 10/18) of 
asymptomatic cases and adults 44% (n= 8/18)
Tabata et al. 
(2020)
General public exposed to 
outbreak on cruise ship
Median age of asymptomatic versus symptomatic participants: 70 (IQR: 57-
75) versus 68 (IQR: 56-74)
Hung et al. 
(2020)
General public exposed to 
outbreak on cruise ship
Median age of asymptomatic and symptomatic participants: 57 (IQR: 47–59) 
versus 68 (IQR: 59–68)
Ladhani et al. 
(2020)
Nursing home residents and 
staff
Median age of asymptomatic, post-symptomatic, pre-symptomatic, and 
symptomatic residents: 84 (IQR: 78-90); 88 (IQR: 85-91); 84 (IQR: 80-91); 87 
(IQR: 80-91) 
 
Median age of asymptomatic, post-symptomatic, pre-symptomatic, and 
symptomatic staff: 
50 (IQR: 40-56); 54, (41-59); 38 (IQR 34-49); 40 (IQR: 26-55)
for PCR-confirmed infections (up to 80%) and highlight 
the importance of distinguishing between asymptomatic and 
pre-symptomatic cases. Heterogeneity in estimates of the 
asymptomatic proportion, however, was partly influenced by 
variation between testing contexts. Subgroup estimates range 
from 6% (95%CI 0-17%) for household contacts, increasing 
to 23% (95% CI 14-32%) for participants with other epide-
miological links to case(s) or outbreaks, and the highest esti-
mate of 47% (95% CI 21-74%) for point prevalence studies 
not directly linked to contact(s)/outbreaks.
These findings should be interpreted with caution in terms 
of the relationship between exposure and symptom sta-
tus38. The assumption that household contacts of index cases 
may experience frequent and intense exposure with limited 
protection compared to other groups, and conversely that par-
ticipants in non-outbreak studies may have more limited expo-
sure, could not be empirically verified in the present review. 
Confidence intervals for subgroup asymptomatic proportions 
overlapped substantially, and data were limited for both the 
household contact and the point prevalence survey with symp-
tom follow-up categories (both n=3 included studies). Further-
more, the estimate for point prevalence surveys was affected 
by one study35 with a very high asymptomatic proportion 
(91%); this estimate was likely influenced by the limited symp-
tomatic case definition of new-onset cough or fever. Estimates 
for the other two studies were similar to the ‘other epidemio-
logical link’ category (26% and 29%). Only one of the point 
prevalence studies with symptom follow-up36 was conducted 
in a general population sample. Furthermore, the ‘other epi-
demiological link’ category comprised a variety of study 
testing contexts, including studies that combined household 
contacts with participants with less intensive exposure, which 
likely contributed to substantial within-category heterogeneity. 
Despite these substantial limitations, further investigation 
is warranted into variability in the asymptomatic proportion 
across testing contexts as more data become available.
This effect of study context may partially account for dif-
ferences between the overall estimate of the asymptomatic 
proportion in the current review and higher estimates from other 
studies. Notably, early population-based data collected from 
English households by the Office for National Statistics sug-
gested that only 22% (95% CI 14-32%) of the 88 individuals 
who tested positive for COVID-19 thus far reported any 
symptoms, rising to 29% (95% CI 19-40%) of the 76 indi-
viduals tested repeatedly8. Similarly, 69% of another English 
community sample recruited regardless of symptom status 
reported no symptoms in the seven days up to their positive 
PCR result39. However, neither of these studies systematically 
followed-up cases regarding their symptoms across the course 
of infection, potentially overestimating the asymptomatic pro-
portion and precluding inclusion in this review. Furthermore, 
findings were affected by the small sample size and conse-
quently wide confidence intervals due to testing at a period of 
relatively low COVID-19 incidence in the population, as well 
as potential false positive PCR tests leading to an overestimate 
of asymptomatic cases. While some of these issues may have 
impacted studies included in the present review, the care-
ful screening of study design and methodology done as part 
of this review was reflected in the overall very low or low 
risk of bias on assessed criteria for all but four included 
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studies. An additional strength of our review is the systematic 
search of both peer-reviewed published literature and preprint 
studies which has enabled us to capture the most up to date 
estimates available.
Although this review identifies PCR-confirmed cases, PCR- 
confirmation and symptom-status alone cannot establish whether 
cases are infectious and, if so, the degree or duration of their 
infectiousness. Case reports, however, have indicated poten-
tial transmission of SARS-CoV-2 from some asymptomatic 
index cases1,2,9,21. The balance of evidence regarding viral load in 
the present review indicates that asymptomatic cases had simi-
lar baseline or overall median viral loads to pre-symptomatic 
and symptomatic cases. Virological evidence suggests that 
infectious SARS-CoV-2 can be isolated by viral culture from 
samples with cycle threshold values up to 33, though the 
proportion of infectious virus decreases at higher cycle thresh-
old values (i.e. lower viral load)40. While median baseline cycle 
threshold values for all symptom status groups (23.1-25.5) 
reported by Arons et al.18 fell well within this limit, infectious 
virus was isolated from only 33% of asymptomatic baseline 
samples, compared to 71% of pre-symptomatic and 65% of 
symptomatic samples. These findings should be interpreted 
with caution given the very small sample of asymptomatic 
specimens (n=3). Overall, clear reporting of cycle threshold 
values across follow-up by symptom status was lacking in 
included studies. This is an important area for further research 
given that the degree and duration of the infectious period 
for asymptomatic cases, as well as the overall proportion of 
virus-shedding cases that are asymptomatic, influence the 
contribution of asymptomatic cases to SARS-CoV-2 transmission 
at a population level.
Evidence regarding the duration of SARS-CoV-2 shedding 
by symptom status was very limited, with two studies sug-
gesting no substantial difference in viral clearance times for 
asymptomatic and symptomatic cases. Duration of shedding 
varied widely between participants across all symptom status 
groups in included studies. The sample of asymptomatic 
cases in studies that reported duration of viral shedding also 
tended to be small, and the natural history of viral excre-
tion by symptom status remains unclear. Further inquiry 
into the degree of preclinical shedding for pre-symptomatic 
cases, although not the focus of this review, is also war-
ranted. The contribution of asymptomatic and pre-symptomatic 
cases to the overall spread of infection cannot be accurately 
inferred in the absence of high-quality evidence assessing the 
infectiousness of such cases41.
Evidence was also split regarding age and symptom status, 
with three studies indicating no difference in age between 
asymptomatic and symptomatic cases and three studies indi-
cating that asymptomatic cases may tend to be younger than 
those with symptoms. Samples in the present study – both 
within the age-related analysis and in the meta-analysis overall 
– tended to comprise primarily or exclusively of adults, and one 
study with a substantial child subsample29 found that a larger 
proportion of infected children were asymptomatic (23%) than 
adults (7%). Further comparison of the asymptomatic proportion 
for children and adults is required.
An important limitation of this review was the variability 
between symptomatic case definitions across included stud-
ies. Only eight of the twenty-one included studies18,22–24,30,32,35,37 
described the full range of symptoms included within 
their symptomatic case definitions, while a further ten 
studies19,20,23,25–29,33,34 reported details of symptoms endorsed by 
participants but did not specify whether or which additional 
symptoms were assessed as part of their case definitions and 
three17,31,36 provided no detail. While a similar range of symptoms 
appear to have been monitored/endorsed across most included 
studies, it is possible that symptomatic case identification 
may have been affected by reporting bias and consequently 
that the true proportion of symptomatic cases was underesti-
mated. Notably, Starling et al.35 – the study with the highest 
reported asymptomatic proportion (91%) – used a very lim-
ited case definition of new-onset cough or fever. The reported 
proportion likely reflects individuals not meeting this case 
definition and excludes cases with other symptom profiles. 
This issue is particularly relevant given that unusual symp-
toms such as dysosmia/anosmia - only explicitly investigated 
by four studies21,28,30,37 - and dysgeusia/ageusia -only explicitly 
investigated by two studies28,30 - may be the primary or sole 
symptom for some COVID-19 cases42–44. Demographic report-
ing across studies was also limited and it was not possible 
to stratify findings by further demographic characteristics. 
Estimates of the asymptomatic proportion may vary across 
population subgroups and this is a relevant area for future 
enquiry.
We included only studies with symptom-related follow-up to 
prevent symptom status misclassification. However, overes-
timation of the asymptomatic proportion may still occur in 
contact tracing studies initiated during established outbreaks, 
such as Graham et al.24., if baseline symptomatic participants 
are classified as index cases and systematically excluded 
from the asymptomatic proportion. This review was also 
limited to estimating the asymptomatic proportion of virologi-
cally confirmed infections. The asymptomatic proportion of 
infection varies depending on whether infections are identified 
using virological or serological methods45. PCR confirmation, 
which identifies infection with viral shedding, is informa-
tive for modelling transmission potential. However, review 
of the asymptomatic proportion of total infections based 
on emerging serological evidence – which identifies infec-
tions regardless of viral shedding – will be informative to 
understand how far SARS-CoV-2 has spread within populations 
and investigate evidence of immunity following asymptomatic 
infection46.
Overall, this review provides preliminary evidence that, when 
investigated using methodologically appropriate studies, a 
substantial minority of SARS-CoV-2 infections with viral 
shedding are truly asymptomatic. These findings indicate that 
testing should not be exclusively limited to symptomatic indi-
viduals. Further research identifying distinguishing features 
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(e.g. age) and testing contexts for truly asymptomatic cases, 
as well as their transmission potential, is recommended 
to inform testing programmes. These findings also high-
light the importance of other public health measures, such 
as promoting social distancing and wearing face coverings 
in public places, regardless of symptom status. 
Data availability
Underlying data
University College London Research Data Repository: A Rapid 
Review and Meta-Analysis of the Asymptomatic Proportion 
of PCR-Confirmed SARS-CoV-2 Infections in Community 
Settings. http://doi.org/10.5522/04/12344135.v347.
This project contains the following underlying data:
•     Asymptomatic meta-analysis V2.csv. (Data used to 
conduct meta-analysis of asymptomatic proportion.)
Reporting guidelines
University College London Research Data Repository: PRISMA 
checklist for ‘A rapid review and meta-analysis of the asymp-
tomatic proportion of PCR-confirmed SARS-CoV-2 infections 
in community settings’. http://doi.org/10.5522/04/12344135.v347.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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